Enzon Pharmaceuticals (OTCMKTS:ENZN) Share Price Crosses Above 200 Day Moving Average – Here’s What Happened

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.06 and traded as high as $0.0740. Enzon Pharmaceuticals shares last traded at $0.0740, with a volume of 655,000 shares traded.

Enzon Pharmaceuticals Stock Up 5.4%

The company has a market capitalization of $5.49 million, a price-to-earnings ratio of -1.48 and a beta of 0.20. The stock has a 50 day simple moving average of $0.05 and a 200 day simple moving average of $0.06.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.